Regulation
Six states announce parallel enforcement; more expected to follow.
Pharmacy boards in six states announced coordinated enforcement against unlicensed GLP-1 distribution this week, the first multi-state action targeting the research-chemical channel specifically rather than compounding pharmacies.
The actions focus on sellers marketing directly for human use — marketing language, dosing instructions, and consumer packaging being the cited factors. Sellers maintaining strict research-use framing were not named in this round.
Apex Peptides holds the top position; Cascade Research Group drops 17 points after failed verification; BioRegen enters the top five.
RankingsInterim results from the TRIUMPH program suggest the triple agonist maintains its lead over dual-incretin therapy on weight and liver-fat endpoints.
ResearchThe August guidance clarifies bulk-substance eligibility and signals enforcement priorities for the next year.
RegulationThe Peptide Institute Weekly
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
